Drugs in ATC Class D06BA

Up to Top Level ATC Classes

Up to D - Dermatologicals

Up to D06 - ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE

Up to D06B - CHEMOTHERAPEUTICS FOR TOPICAL USE

Drugs in ATC Class: D06BA - Sulfonamides

Tradename	Generic Name
SILVADENE	silver sulfadiazine
SSD	silver sulfadiazine
SSD AF	silver sulfadiazine

D06BA Market Analysis and Financial Projection

The ATC Class D06BA - Sulfonamides encompasses antimicrobial sulfonamide drugs used topically for dermatological infections, such as silver sulfadiazine (D06BA01) and sulfathiazole (D06BA02). These drugs inhibit bacterial folate synthesis, treating conditions like burns, wounds, and skin infections[1][6]. Below is an analysis of their market dynamics and patent landscape:

---

Market Dynamics

Current Market Overview

• The global sulphonamides market was valued at USD 123.39 million in 2023, projected to grow at a 5.19% CAGR through 2030[4][13].
• Topical sulfonamides (e.g., D06BA drugs) dominate applications due to their efficacy in treating skin infections, which accounted for 27.7% of revenue in 2023[13].
• Key drivers:
  • Rising bacterial infections, including hospital-acquired infections (HAIs) and drug-resistant tuberculosis[14].
  • Increasing use in emerging markets with improving healthcare infrastructure[13].

Segmentation

Segment	Details
Route of Administration	Oral (USD 66.2 million in 2023), topical (fastest-growing)[13].
Applications	Skin infections (largest share), UTIs, respiratory infections[13].
Distribution	Hospital pharmacies lead due to prescriptions for severe infections[13][14].

Regional Insights

• North America holds a major share (e.g., U.S. sulfonamides market: USD 48 million in 2023), driven by high TB incidence and advanced healthcare[14].
• Asia-Pacific is growing rapidly (5.3% CAGR) due to increased healthcare spending and infectious disease prevalence[13].

---

Patent Landscape

Key Patents and Innovations

• Synthesis Methods:
  • US20030236437A1[16]: Describes a process for preparing sulfonamides using aniline derivatives and sulfonating agents.
  • WO2017031599A1[15]: Covers sulfonamide-containing antimicrobials for substrate treatments (e.g., fabrics).
• Formulation Patents:
  • US2411495A[5]: Focuses on derivatives of sulfonamides with enhanced efficacy.

Trends and Challenges

• Expiring Patents: Leading to generic competition, as seen with older sulfonamides like sulfanilamide[8][17].
• Strategic Filings: Major players like Pfizer and Teva focus on jurisdiction-specific patents (e.g., China, U.S., Europe) to prolong market exclusivity[9][10].
• Innovation Gaps: Limited recent patents for novel D06BA drugs, signaling reliance on existing compounds[11][15].

---

Competitive Landscape

• Top Players: Pfizer, Teva, Roche, and Viatris dominate, leveraging branded drugs and generics[4][13].
• Branded vs. Generic: Branded drugs lead revenue (2023), but generics are gaining traction in cost-sensitive markets[13].

---

Future Outlook

• Growth Opportunities: Development of combination therapies (e.g., sulfonamides + antifungals) and novel delivery systems[6][15].
• Threats: Antibiotic resistance and regulatory hurdles for new approvals[14].

---

Highlight: "Sulfonamides remain a cornerstone in treating bacterial skin infections, but their future hinges on overcoming resistance and patent cliffs." [4][13]

---

Key Takeaways

1. D06BA sulfonamides are critical for topical infections, driving steady market growth.
2. Patent expirations and generic competition are reshaping the competitive landscape.
3. Regional disparities in demand highlight opportunities in Asia-Pacific and Africa.

FAQs

1. What are common D06BA drugs?
   Silver sulfadiazine (burns), sulfathiazole (wound infections).
2. Why are sulfonamides still used despite resistance?
   Cost-effectiveness and efficacy in specific applications (e.g., dermatology).
3. Which companies lead in sulfonamide production?
   Pfizer, Teva, and Roche.
4. How do patents affect market access?
   Expired patents enable generics, reducing prices but increasing competition.
5. What’s the future of D06BA drugs?
   Focus on combination therapies and novel formulations to combat resistance.

References

1. https://www.kegg.jp/entry/D00433
2. https://atcddd.fhi.no/atc_ddd_index/?code=D06BA06
3. https://pubchem.ncbi.nlm.nih.gov/compound/Sulfathiazole
4. https://www.grandviewresearch.com/industry-analysis/sulphonamides-market-report
5. https://patents.google.com/patent/US2411495A/en
6. https://en.wikipedia.org/wiki/ATC_code_D06
7. https://pharmacy.moh.gov.my/sites/default/files/document-upload/msom-2018-2022-15102024_0.pdf
8. https://pubchem.ncbi.nlm.nih.gov/compound/5333
9. https://unitaid.org/uploads/TMC_207_Patent_Landscape.pdf
10. https://www.patentnext.com/2024/08/wipo-issues-a-patent-landscape-report-on-generative-artificial-intelligence-genai/
11. https://www.knowmade.com/patent-analytics-services/patent-report/life-sciences-patent-landscape/allogeneic-car-patent-landscape-analysis-2023/
12. https://list.essentialmeds.org/files/trs/KmctuAAMtPBorqeQRged3u44S6eeGKQPvOfhGr65.pdf
13. https://www.gminsights.com/industry-analysis/sulphonamides-market
14. https://www.mordorintelligence.com/industry-reports/sulphonamides-market
15. https://patents.google.com/patent/WO2017031599A1/en
16. https://patents.google.com/patent/US20030236437A1/en
17. https://pubchem.ncbi.nlm.nih.gov/compound/Sulfadiazine